Precision Therapeutics (NASDAQ:POAI) Raised to “Buy” at ValuEngine
Shares of NASDAQ:POAI traded up $0.01 during trading on Tuesday, hitting $3.01. 48,013 shares of the company’s stock traded hands, compared to its average volume of 12,385. The company has a debt-to-equity ratio of 0.02, a current ratio of 0.10 and a quick ratio of 0.08. The firm has a 50-day simple moving average of $2.89. Precision Therapeutics has a 52 week low of $2.35 and a 52 week high of $11.50.
An institutional investor recently bought a new position in Precision Therapeutics stock. Vanguard Group Inc. acquired a new position in shares of Precision Therapeutics Inc (NASDAQ:POAI) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 155,934 shares of the medical instruments supplier’s stock, valued at approximately $115,000. Vanguard Group Inc. owned approximately 0.51% of Precision Therapeutics as of its most recent SEC filing. Hedge funds and other institutional investors own 10.89% of the company’s stock.
Predictive Oncology Inc provides various healthcare products and services primarily in the United States. The company manufactures environmentally conscious systems for the collection and disposal of infectious fluids that result from surgical procedures and post-operative care. It offers the STREAMWAY Fluid Waste Management system that suctions surgical waste fluid from the patient using standard surgical tubing; and disposables.
Featured Article: What is the market perform rating?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Precision Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Precision Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.